Insider Brief
- Quantum Circuits, Inc. announced that its partner Algorithmiq is accelerating drug discovery using the Aqumen Seeker quantum computing system.
- Algorithmiq develops quantum algorithms that improve molecular simulations and enable faster, complex calculations beyond classical computing capabilities.
- Quantum Circuits’ dual-rail qubit technology provides built-in error detection, supporting more reliable and scalable quantum computing for pharmaceutical applications.
PRESS RELEASE — Quantum Circuits, Inc. announced that its partner Algorithmiq, a European quantum algorithm company focused on life sciences, is accelerating new drug discovery by utilizing the full-stack quantum computing system Aqumen Seeker to detect errors and produce more accurate chemistry calculations.
In its partnership with Quantum Circuits, Algorithmiq creates quantum algorithms that efficiently address use cases throughout healthcare and life sciences. These efforts include detailed molecular simulations that predict important properties like enzyme pharmacokinetics. The company’s drug discovery approach requires quantum algorithms that enable faster, complex calculations that cannot be achieved by traditional classical computers alone.
Quantum Circuits provides Algorithmiq with a pragmatic, efficient path to reliable calculations. Its Aqumen Seeker is a full-stack quantum computing system that follows a “correct first, then scale” approach. Featuring the industry’s only dual-rail qubits with built-in error detection, Seeker allows Algorithmiq to design algorithms that dramatically lessen the impact of errors and bypass inefficient brute-force techniques that limit the quantum industry’s commercial readiness.
“At Algorithmiq, we are demonstrating how quantum computing can transform drug discovery with practical, scalable solutions,” said Sabrina Maniscalco, CEO of Algorithmiq. “Our recent results provide a proof-of-concept implementation of a scalable quantum pipeline, showing how error-aware quantum algorithms can be applied to tackle one of the most fundamental challenges in drug discovery. Partnering with Quantum Circuits and leveraging their unique dual-rail qubit technology will allow us to further refine and scale these techniques, accelerating real-world impact in pharmaceutical innovation.”
“Algorithmiq’s work represents a welcome chapter in the quantum industry’s maturation from science projects to commercial readiness,” Quantum Circuits CEO Ray Smets said. “Aqumen Seeker’s dual-rail qubits with built-in error detection pave the way to repeatable, consistent, and trusted quantum computing that enterprises can bet their businesses on. The possibility of certain breakthroughs in health and life sciences have been historically confined to dreams – until now.”
The announcement of Algorithmiq as a partner represents the latest chapter in Quantum Circuits’ recent emergence from stealth mode. Founded in 2015 by superconducting qubit pioneers out of Yale University, including Robert Schoelkopf, the company spent years developing error detection technology as part of its comprehensive quantum computing system. Last year, Quantum Circuits announced a $60 million Series B round and the launch of Aqumen Seeker.
